Inhibiting GSDMD is sufficient to suppress the overall neuroinflammatory response, shedding new light on the inhibition of excessive early (1–5 days) neutrophil mobilization and brain neutrophilia and informing future anti-inflammatory interventions in patients with AIS. Here, GSDMD is linked to androgen insensitivity syndrome.